COMPASS Report
CANCER – Strategy for affordable care
The cancer burden is growing globally. Each year >18 million people are diagnosed, nearly 10 million die and the estimated economic cost exceeds $1 trillion. From early diagnosis to late-stage disease, cancer care often involves inappropriate or unnecessary interventions that drive costs but provide limited clinical benefit. Coupled with an increased understanding of cancer biology and rapid technological advances, this has been driving momentum for precision medicine, leading to patient and societal benefits. The use of biomarkers and sophisticated diagnostics is facilitating early intervention through robot-enabled minimally invasive surgery and locally delivered radiotherapy, while immuno-oncology is revolutionising late-stage cancer care.
This report is a roadmap to investable technologies in oncology. We analyse the drivers and industrial solutions to the cancer cost curve, assess clinically relevant health technologies to fight cancer, and highlight attractive sub-sectors.